Manifold Innovative Immunology Products Are Currently in Development, Says GBI Research in Its Study Recently Published at MarketPublishers.com
23 Feb 2017 • by Natalie Aster
LONDON – Immunology is a vast therapy area characterised by disfunctions of the immune system. There are 2,145 products in active development relating to this disease area, trailing only infectious diseases, oncology and mental breakdowns with respect to pipeline size. All together, there are 529 immunology products in clinical development that take effect on top-of-the-range molecular targets, capturing close to 40% of the total immunology pipeline for which the molecular target was discovered.
Owing to a level of crossover between immunology-related indications relating to their underlying pathophysiology, it is not unusual for drugs being developed for this field to have developmental programmes exploring them across numerous indications.
Nearly one-fifth of best-in-class pipeline drug products are in clinical development for 2 or more indications within the therapeutic category. This opens up an opportunity for firms to develop a range of innovative products across manifold immune disorders, and hence reach a larger patient pool than products meant for single indications.
In-demand research report “Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential” elaborated by GBI Research gives a detailed look at the market performance.
The report gives an overview of the current clinical and commercial landscapes by looking at disease etiology, symptoms, co-morbidities, treatment options, etc. It identifies the top products and firms in the marketplace, and uncovers the burning unmet needs. The study examines key trends in pipeline by considering the therapies by development stage, molecule type and molecular target, and identifies key innovation trends in each segment. It also gives a detailed assessment of the therapeutic potential of first-in-class targets, points out promising best-in-class pipeline assets that are appropriate for in-licensing.
More in-demand market reports by the publisher are available at GBI Research page.